Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.65 |
| ▸ | NAAA | Q02083 | 1/20 | 0.61 |
| ▸ | FAAH | O00519 | 5/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9518701 | 0.95 | CASP2 (0.71) | CASP2NAAAFAAHEPHX2EPHX1 | |
| SCHEMBL9502450 | 0.95 | CASP2 (0.71) | CASP2NAAAFAAHEPHX2EPHX1 | |
| SCHEMBL1146790 | 0.95 | CASP2 (0.71) | CASP2NAAAFAAHEPHX2EPHX1 | |
| SCHEMBL9518772 | 0.93 | CASP2 (0.68) | CASP2NAAAFAAHEPHX2EPHX1 | |
| SCHEMBL2616429 | 0.91 | CASP2 (0.67) | CASP2NAAAFAAHEPHX2EPHX1 | |
| SCHEMBL23394708 | 0.88 | CASP2 (0.62) | CASP2NAAAFAAHEPHX2EPHX1 | |
| SCHEMBL12192205 | 0.88 | CASP2 (0.62) | CASP2NAAAFAAHEPHX2EPHX1 | |
| SCHEMBL21779474 | 0.88 | CASP2 (0.61) | CASP2NAAAFAAHEPHX2SLC6A5 | |
| SCHEMBL12523062 | 0.87 | CASP2 (0.59) | CASP2NAAAFAAHEPHX2EPHX1 | |
| SCHEMBL28343752 | 0.87 | CASP2 (0.61) | CASP2NAAAFAAHEPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241233-A1 | ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING LIPID CONJUGATES | UNIVERSITAT HEIDELBERG (DE) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241233-A1 | ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING LIPID CONJUGATES | CETP, PHOSPHO1, NPC1L1 | CASP2 1850/4885NAAA 428/4885FAAH 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.